Wikipedia

Nicotinic agonist

A nicotinic agonist is a drug that mimics the action of acetylcholine (ACh) at nicotinic acetylcholine receptors (nAChRs). The nAChR is named for its affinity for nicotine.

Examples include nicotine (by definition), acetylcholine (the endogenous agonist of nAChRs), choline, epibatidine, lobeline, varenicline and cytisine.[1]

History

edit
 
Chemical structure of ABT-418

Nicotine has been known for centuries for its intoxicating effect. It was first isolated in 1828 from the tobacco plant by German chemists Posselt and Reimann.[2]

The discovery of positive effects from nicotine on animal memory was discovered by in vivo researches in the mid 1980s. Those researches led to a new era in studies of nicotinic acetylcholine receptor (nAChR) and their stimulation but until then the focus had mainly been on nicotine addiction.[3][4] The development of nAChR agonists began in the early 1990s after the discovery of nicotine's positive effects. Some research showed a possible therapy option in preclinical researches. ABT-418 was one of the first in a series of nAChR agonists and it was designed by Abbott Labs.[4] ABT-418 showed significant increase of delayed matching-to-sample (DMTS) performance in matured macaque apes of different species and sex.[5] ABT-418 has also been examined as a possible treatment to Alzheimer's disease, Parkinson's disease and attention-deficit hyperactivity disorder: those experiments showed positive outcomes.[4]

One of the first nAChR active compounds, besides nicotine, that was marketed as a drug was galantamine, a plant alkaloid that works as a weak cholinesterase inhibitor (IC50 = 5 μM) as well as an allosteric sensitizer for nAChRs (EC50=50 nM).[6]

Nicotinic acetylcholine receptors and their signaling system

edit
 
Nicotinic acetylcholine receptor classification

Signaling system

edit

In the human nervous system nicotinic cholinergic signals are extended throughout the system, where the neurotransmitter acetylcholine (ACh) plays a key role in activating ligand-gated ion channels.[7] The cholinergic system is a vital nervous pathway, where cholinergic neurons synthesize, store and release the neurotransmitter ACh. The main receptors that convert the ACh messages are the cholinergic muscarinic acetylcholine receptors, neuronal and muscular nAChRs. When looking back at evolutionary history, ACh is considered to be the oldest transmitter molecule and became present before the nervous cell. In the nervous system cholinergic stimulation mediated through nAChRs controls pathways such as release of transmitters and cell sensitivity, which can influence physiological activity including sleep, anxiety, processing of pain and cognitive functions.[8]

Nicotinic acetylcholine receptors

edit

nAChRs are cholinergic receptors found in the central nervous system (CNS), peripheral nervous systems (PNS) and skeletal muscles, these receptors are ligand-gated ion channels with binding sites for acetylcholine and other molecules. When ACh or other agonists bind to the receptors it stabilizes the open state of the ion channel allowing influx of cations such as potassium, calcium and sodium ions. The nAChRs are made up by different subunits which determine the quaternary structure of the receptor, those subunits are α subunits (α1−α10), β subunits (β1−β4), one δ subunits, one γ subunit and one ε subunit. nAChRs can be either heteromeric or homomeric. The heteromeric receptors found in the central nervous system are made up by two α subunits and three β subunits with the binding site at the interface of α and the adjacent subunit. These receptors contain two binding sites per receptor and have different affinity for chemicals based on the composition of subunits. Both binding sites work together and thus, both sites need to be occupied with a nAChR agonist so that channel activation can take place.[9] nAChRs containing α2−α6 and β2−β4 subunits have been shown to have higher affinity for ACh than other receptors. Homomeric receptors contain 5 identical subunits, they have 5 binding sites located at the interface between two adjacent subunits. In the year 2000 two homomeric receptors had been identified in humans, the α7 and α8 receptors.[8][10][11][12]

Binding site

edit

There are two binding sites on heteromeric nAChRs; to stabilize the open form of nAChRs, both binding sites must be occupied by agonist, such as nicotine or ACh.[11]
The ACh binding site of nAChR is made up by six loops, termed A–F. The A, B and C loops of the binding site are part of the α subunit and are the principal components of the binding site. The adjacent subunit to the α subunit (γ, δ, ε or β) contains the D, E and F loops.[11]

Mechanism of action

edit
 
Two different subtypes of nicotinic acetylcholine receptors

α4β2 receptor agonists

edit

α4β2 nAChRs contain two α4 subunits and three β2 subunits, therefore it has two binding sites for ACh and other agonists. α4β2 nAChRs account for approximately 90% of the nAChRs in the human brain and when chronically exposed to nicotine or other nicotine agonists leads to increase in density of α4β2 receptors which is the opposite of what usually happens when other receptors are chronically exposed to their agonists. The α4β2 receptor has been widely studied in regards to Alzheimer's disease as well as for nicotine dependence and in 2009 several drugs are on the market that target the α4β2 nAChR specifically.[13][14]

α7 receptor agonists

edit

α7 receptors are homomeric neuronal acetylcholine receptors consisting of five α7 subunits and has five ACh binding sites. Abnormality in the α7 receptors expression have been reported to influence progression of diseases such as Alzheimer's disease and schizophrenia. The α7 are not believed to have as much affinity for nicotine as the heteromeric receptor but instead they have shown more affinity for alpha bungarotoxin which is a nicotinic antagonist found in venom of some snakes. Targeting of α7 receptors is therefore thought to be useful in treatment of Alzheimer's disease and schizophrenia.[9][15]

Muscle type receptor agonists

edit

nAChR are found in the neuromuscular junction on skeletal muscles. Two different receptors have been found, one of which has primarily been found in adults contains two α1 subunits, one β1, one ε and one δ, the other one has been found in fetuses and contains γ subunit instead of the ε subunit. The nAChRs take part in the depolarization of the muscular endplate by increasing cation permeability leading to contraction of skeletal muscles.[16] The nAChRs found in the skeletal muscle system have two ACh binding sites, one of which is found at the interface between α1 and δ subunits while the other one is found at the interface between α1 and γ or ε subunits. Among nAChR antagonists designed specifically for the neuromuscular system are nerve gases and other poisons designed to quickly kill humans or other animals and insects.[12]

Binding

edit

ACh binds to nAChR because of charge difference between the molecule and the surface of the receptor. When binding to nAChR ACh fits into a binding pocket shaped by loops A, B and C which belong to α subunit and the adjacent subunit. When ACh is fitted into the binding pocket the loops of the nAChR undergo movement that leads to a coordination of the ACh molecule in the pocket enhancing the chemical bonds between the molecule and the receptor. After movement of the loops that belong to α subunit it's sometimes possible for the ACh molecule to form a bond, e.g. salt bridge, to the adjacent subunit enhancing the bonds between the receptor and ACh even further.[17]

Drug design

edit

Drugs that influence nAChRs can be agonists, partial agonists or antagonists.[1] Agonists, e.g. nicotine, can however act as depolarizing agents when encountered to nAChRs for some time (seconds or minutes, depending on concentration and nAChR subtype), chronic exposure to agonist can also lead to long lasting functional deactivation because of rapid and persistent desensitization. Partial nAChR agonists have been studied since they seem to be helpful in smoking cessation. The partial agonists are believed to bind to the nAChRs and stimulate the release of dopamine in smaller portions than the agonists and therefore compensate for the absence of nicotine.[18]
The lack of specificity among some of the nicotinic agonists is well known and is a potential problem when using them to treat illnesses that require targeting a specific subtype of nAChRs. Among these nonspecific agonists are for example ACh, nicotine and epibatidine that all target more than one subtype of nAChRs.[19][20]

Pharmacophore

edit
 
Chemical structure of nicotine

The development of nAChR agonist pharmacophore started in 1970 when it was proposed that the binding of the agonists to a receptor was dependent on a positively charged nitrogen atom and a hydrogen bond forming from carbonyl oxygen atom in acetylcholine or a nitrogen atom in (S)-nicotine. Since then it has been shown that a cationic center, atoms that are electronegative and able to form hydrogen bonds along with the center of the pyridine ring in (S)-nicotine are favorable. Stereochemistry is a part of the pharmacophore as is clearly seen with (S)- and (R)- nicotine where the (S)-enantiomer is 10-100 times more potent. The azabicyclic ring of epibatidine is another example of favorable steric interactions to the receptors. It has been suggested that a specific internitrogen distance, N+-N, is important for agonist affinity but debate has arisen over its influence. A newer theory is that a distance of 7-8 Å between points that complement the protonated nitrogen atom and hydrogen bond acceptor will enhance the potency. Low electronic density close to the protonated nitrogen and higher electron density close to the pyridine ring is favored in protonated nicotine ligands containing pyridine ring. In later years researchers have taken more interest in the α7 and α4β2 subtype receptors in drug development to treat nicotine dependence and cognitive impairment such as Alzheimer's.[21]

Structure-activity relationships

edit

Structure-activity relationships: Muscle nAChR agonists

edit

Various models have been run where the affinity of nAChR agonists to the receptor subtype are tested to help identify the molecules, groups and steric conformation that are vital to greater affinity. By using a nAChR muscle receptor subtype (α1)2β1δγ model the following results were obtained:

anatoxin > epibatidine > acetylcholine > DMPP >> cytisine > pyrantel > nicotine > coniine > tubocurare > lobeline,

where anatoxin had the highest activity efficacy and tubocurare the lowest. Acetylcholine on the other hand induced a much longer opening time of the receptor though anatoxin is more potent. The results suggest that anatoxin derivatives would be helpful in understanding structure-activity relationships (SAR) for muscle nAChRs.[22]

Succinylcholine chloride, which is a drug that's already on the market, is a bischoline ester and a short acting muscle relaxant. Bischoline esters are compounds that can act as a competitive agonist on muscle type nAChRs and have been used in SAR studies. In a Torpedo (α1)2β1δγ nAChR model it was demonstrated that the potency of bischoline ester agonists is dependent on the chain length as potency increases with longer chains. Efficacy seems to be independent of chain length since the highest efficacy is seen in bischoline esters with four to seven CH
2 units and is lower for both fewer CH
2 units and more.[23]

Structure-activity relationships: α4β2 nAChR agonists

edit
 
Pyridin cyclopropan derivatives

Combination of structural elements of ACh and nicotine as well as reducing the conformational flexibility by using a cyclopropane ring has led to the discovery of potent and selective α4β2 nAChR ligands. The modulation of three structural elements, the linker, substitution on the amino group and the pyridine ring can be used to determine the influence on potency and selectivity of the ligands. Factors that decrease the binding are steric hindrance on the amino group and linkers that are saturated/unsaturated carbon chains. Short-chained ether linkers are preferred. Beneficial effects on the binding is seen with substitution on the pyridine ring both mono- and disubstitution with halogens among other groups. Substitution on the amino group with three different amides increased the binding affinity where methylamide had the highest binding. Lower binding in the other substituted amides was explained by steric hindrance or lack of a methyl group resulting in loss of hydrophobic interaction. Stereochemistry of pyridine nitrogen and/or the pyridine ring and its stereoelectronic effects has a subtle beneficial effect on the binding to the α4β2 nAChR. Thus it was shown that a pyridyl ether ligand with bromo substitution on the pyridine and metylatedamide on the amino group had the highest potency.[24]

Structure-activity relationships: α7 nAChR agonists

edit
 
SEN12333/WAY-317538
 
Structure activity relationship model for α7 agonists

The search for selective and potent α7 nAChR agonists has produced a series of compounds that have good potential as drug candidates. One such search produced SEN12333/WAY-317538 among other compounds that have desirable pharmacokinetic profiles and are selective of α7 nAChRs over α1, α3 and α4β2 nAChRs. Structure activity relationships for these compounds have been proposed.[15] The optimal pharmacophore of α7 nAChR agonist is made of three parts. There is a basic moiety connected to a carbon chain linked to an aromatic moiety by an amide bridge. The amide bridge can be inverted without affecting the potency of the agonist. A biaryl group shows more potency than a monoaryl group as the aromatic moiety and substitution at position 2 on the later aryl group will further increase the potency. Potency is higher for agonists with H+ donor/acceptor on the later aryl group on the biaryl group. A high number of hydrogen bond acceptors could decrease permeability across the blood–brain barrier (BBB) due to the polar surface area and needs to be taken into account when designing agonists to target α7 nAChRs.[15]

Various cyclic amine groups can act as the basic moiety and potency stays relatively unchanged for example aryl piperazine, piperidine and morpholine. An acyclic tertiary amine is tolerated as the basic moiety but larger steric groups are less tolerated.[15]

Many derivatives of quinuclidine such as quinuclidine amide are known to be α7 nAChR agonists. SAR studies for quinuclidine amide have identified factors that are affecting the potency and affinity of these agonists. Para substitution on the quinuclidine ring and the 3-(R) configuration in the stereochemistry is favored. Enhanced activity is observed when a 5 membered ring is fused to aromatic moiety. Further enhancement is seen when the fused ring is able to supply electron resonance to the amide carbonyl whereas the activity will diminish when the fused ring contains a hydrogen bond donating atom. The rigidity of quinuclidine and the orthogonal orientation of the nitrogen bridge in relations to the amide carbonyl group is presumed important for the optimal binding. The stability of some of the more potent quinuclidine amide derivatives in rat in vitro models have been low however by adding a methyl group to position 2 on the quinuclidine ring the stability has increased greatly.[25]

Drug development

edit

The development of nicotinic acetylcholine receptor agonists began in the early 1990s after the discovery of nicotine's positive effects on animal memory.[3][4] The development of nicotinic acetylcholine receptor agonists has come a long way since then. Nicotinic acetylcholine receptor agonists are gaining increasing attention as drug candidates for multiple central nervous system disorders such as Alzheimer's disease, schizophrenia, attention-deficit hyperactivity disorder (ADHD) and nicotine addiction.[26][27] Nicotinic acetylcholine receptors are receptors found in the central nervous system, the peripheral nervous systems and skeletal muscles. They are ligand-gated ion channels with binding sites for acetylcholine as well as other agonists. When agonists bind to a receptor it stabilizes the open state of the ion channel allowing influx of cations.[9]

In 2009 there were at least five drugs on the market that affect the nicotinic acetylcholine receptors.

Quinuclidine derivatives
     
Quinuclidine carbamates Quinuclidine amides Quinuclidine ethers

Products of nicotinic agonist

edit
Active ingredient Product name Chemical name Pharmaceutical form Pharmacodynamic properties Therapeutic use Structure
Varenicline tartrate Champix, Chantix 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine[27] Film coated tablet Partial agonist of the nicotinic acetylcholine receptor, subtype α4β2[28] Treatment of tobacco dependence[28]  
Galantamine hydrobromide Reminyl, Nivalin, Razadyne and Razadyn ER 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]-benzazepin-6-ol[29] Sustained release capsule, film coated tablet, oral solution Cholinesterase inhibitor and a noncompetitive agonist of the nicotinic acetylcholine receptor[4] Treatment of dementia caused by Alzheimer's disease[30]  
Nicotine Nicorette, Nicotinell, Niquitin, Boots NicAssist, Commit, Habitrol, Nicoderm CQ, Nicotrol, Thrive 3-[(2S)-1-methylpyrrolidine-2-yl]pyridine Transdermal patch, gum, inhaler, nasal spray, lozenge, microtab, and is naturally found in tobacco Agonist of the nicotinic receptor,[31] both Ganglion type and α4β2[32] Treatment of tobacco dependence[33]  
Carbachol Miostat 2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium Intraocular solution Cholinergic agonist[34] Treatment of glaucoma  
Suxamethonium chloride (Succinylcholine chloride) Anectine, Quelicin Suxamethonium Chloride 2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium) Intravenous or intramuscular injection Depolarizing neuromuscular blocking agent[35] Short acting muscle relaxant[36]  
Epibatidine Not listed 2-(6-chloropyridin-3-yl)-7-azabicyclo[2.2.1]heptane Not listed Agonist of the nicotinic acetylcholine receptor[37] Not used as a drug  

Other nicotinic agonists, albeit generally with limited clinical use, include:

Nicotinic versus muscarinic activity

edit
Comparison of cholinergic agonists[38]
Substance Receptor specificity Hydrolysis by
acetylcholinesterase		 Comments
Muscarinic Nicotinic
Choline +++ +++ ++ Essential nutrient
Acetylcholine +++ +++ +++ Endogenous ligand
Carbachol ++ +++ - Used in the treatment of glaucoma
Methacholine +++ + ++
Bethanechol +++ - - Used in bladder and
gastrointestinal hypotonia.
Muscarine +++ - - Natural alkaloid found in certain mushrooms. Cause of mushroom poisoning
Nicotine - +++ - Natural alkaloid found in the tobacco plant.
Pilocarpine ++ - - Used in glaucoma
Oxotremorine ++ - -

Current status

edit

Currently nicotine receptor agonist research and drug designing is aimed for treatment of multiple diseases and disorders of the CNS.[39]

Targacept has three drug candidates that are in clinical trials; AZD3480 (TC-1734) for ADHD which is currently in phase II clinical trials, AZD1446 (TC-6683) for Alzheimer's disease in collaboration with AstraZeneca and TC-5619 for cognitive dysfunctions in schizophrenia.

Memory pharmaceuticals with its partner Roche has one drug candidate, MEM 3454 (RG3487), a partial agonist of the nicotinic α7 receptor, for Alzheimer's disease.[40][41]

Abbott Laboratories in partnership with NeuroSearch have two drug candidates in clinical trials, ABT-894, a selective α4β2 nicotine receptor agonist, for ADHD and ABT-560, a neuronal nicotinic receptor modulator, which was selected by Abbott in 2006 as a new development candidate for cognitive dysfunctions.[42]

EnVivo pharmaceuticals has one drug candidate in clinical trials, EVP-6124, a selective α7 nicotine receptor agonist for Alzheimer's disease and schizophrenia and one follow-up compound, EVP-4473, that has successfully completed pre-clinical development.[43]

See also

edit

References

edit
  1. ^ a b Matera, Carlo; Papotto, Claudio; Dallanoce, Clelia; De Amici, Marco (August 2023). "Advances in small molecule selective ligands for heteromeric nicotinic acetylcholine receptors". Pharmacological Research. 194: 106813. doi:10.1016/j.phrs.2023.106813. hdl:2434/978688.
  2. ^ Henningfield, Jack E; Zeller, Mitch (2006), "Nicotine psychopharmacology research contributions to United States and global tobacco regulation: a look back and a look forward", Psychopharmacology, 184 (3–4): 286–291, doi:10.1007/s00213-006-0308-4, PMID 16463054, S2CID 38290573
  3. ^ a b Haroutunian, Vahram; Barnes, Edward; Davis, KL (1985), "Cholinergie modulation of memory in rats", Psychopharmacology, 87 (3): 266–271, doi:10.1007/BF00432705, PMID 3001803, S2CID 20040918
  4. ^ a b c d e Buccafusco, J. J. (2004), "Neuronal nicotinic receptor subtypes: defining therapeutic targets" (PDF), Molecular Interventions, 4 (5): 285–295, doi:10.1124/mi.4.5.8, PMID 15471911
  5. ^ Buccafusco, J. J.; Jackson, W. J.; Terry Jr, AV; Marsh, KC; Decker, MW; Arneric, SP (1995), "Improvement in performance of a delayed matching-to-sample task by monkeys following ABT-418: a novel cholinergic channel activator for memory enhancement", Psychopharmacology, 120 (3): 256–266, doi:10.1007/BF02311172, PMID 8524972, S2CID 23215696
  6. ^ Ludwig, J.; Höffle-Maas, A. (2010), "Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain", Journal of Receptors and Signal Transduction, 30 (6): 469–483, doi:10.3109/10799893.2010.505239, PMID 21062106, S2CID 9160835
  7. ^ Liu, Zhaoping; Zhang, J; Berg, Darwin K. (2007), "Role of endogenous nicotinic signaling in guiding neuronal development", Biochemical Pharmacology, 74 (8): 1112–1119, doi:10.1016/j.bcp.2007.05.022, PMC 2116993, PMID 17603025
  8. ^ a b Gotti, C.; Clementi, F. (2004), "Neuronal nicotinic receptors: from structure to pathology", Progress in Neurobiology, 74 (6): 363–396, doi:10.1016/j.pneurobio.2004.09.006, PMID 15649582, S2CID 24093369
  9. ^ a b c Paterson, David; Nordberg, Agneta (2000), "Neuronal nicotinic receptors in the human brain", Progress in Neurobiology, 61 (1): 75–111, doi:10.1016/s0301-0082(99)00045-3, PMID 10759066, S2CID 27207955
  10. ^ Sala, F.; Nistri, A.; Criado, M. (2008), "Nicotinic acetylcholine receptors of adrenal chromaffin cells", Acta Physiologica, 192 (2): 203–212, doi:10.1111/j.1748-1716.2007.01804.x, PMID 18005395, S2CID 29310750[dead link‍]
  11. ^ a b c Itier, Valérie; Bertrand, Daniel (2001), "Neuronal nicotinic receptors: from protein structure to function", FEBS Letters, 504 (3): 118–125, doi:10.1016/S0014-5793(01)02702-8, PMID 11532443
  12. ^ a b Lindstrom, JM (2003), "Nicotinic acetylcholine receptors of muscles and nerves", Annals of the New York Academy of Sciences, 998: 41–52, doi:10.1196/annals.1254.007, PMID 14592862, S2CID 84583356[dead link‍]
  13. ^ Mihailescu, Stefan; Drucker-Colín, René (2000), "Nicotine, Brain Nicotinic Receptors, and Neuropsychiatric Disorders", Archives of Medical Research, 31 (2): 131–144, doi:10.1016/S0188-4409(99)00087-9, PMID 10880717
  14. ^ Arias, Hugo R. (1997), "Topology of ligand binding sites on the nicotinic acetylcholine receptor", Brain Research Reviews, 25 (2): 133–191, doi:10.1016/S0165-0173(97)00020-9, PMID 9403137, S2CID 26453010
  15. ^ a b c d Haydar, Simon N.; Ghiron, Chiara; Bettinetti, Laura; Bothman, Hendrick; Comery, Thomas A.; Dunlop, John; La Rosa, Salvatore; Micco, Iolanda; Pollastrini, Martina; Quinn, Joanna; Roncarati, Renza; Scali, Carla; Valacchi, Michela; Varrone, Maurizio; Zanaletti, Riccardo (2009), "SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist", Bioorganic & Medicinal Chemistry, 17 (14): 5247–5258, doi:10.1016/j.bmc.2009.05.040, PMID 19515567
  16. ^ Brunton, Laurence L.; Lazo, John S.; Parker, Keith L., eds. (2006), Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 ed.), McGRAW HILL, ISBN 978-0-07-142280-2
  17. ^ Unwin, Nigel (2004), "Refined Structure of the Nicotinic Acetylcholine Receptor at 4 A° Resolution", Journal of Molecular Biology, 346 (4): 967–989, doi:10.1016/j.jmb.2004.12.031, PMID 15701510
  18. ^ Cassels, Bruce K.; Bermúdez, Isabel; Dajas, Federico; Abin-Carriquiry, J. Andrés; Wonnacott, Susan (2005), "From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research", Drug Discovery Today, 10 (23–24): 1657–1665, doi:10.1016/S1359-6446(05)03665-2, hdl:10533/176659, PMID 16376826
  19. ^ Matera, Carlo; Papotto, Claudio; Dallanoce, Clelia; De Amici, Marco (August 2023). "Advances in small molecule selective ligands for heteromeric nicotinic acetylcholine receptors". Pharmacological Research. 194: 106813. doi:10.1016/j.phrs.2023.106813. hdl:2434/978688.
  20. ^ Gotti, C.; Fornasari, D.; Clementi, F. (1997), "Human Neuronal Nicotinc Receptors", Progress in Neurobiology, 53 (2): 199–237, doi:10.1016/S0301-0082(97)00034-8, PMID 9364611, S2CID 10421687
  21. ^ Tøndera, Janne E.; Olesena, Preben H.; Hansena, John Bondo; Begtrupb, Mikael; Petterssona, Ingrid (2001), "An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled by [3H]-N-methylcarbamylcholine", Journal of Computer-Aided Molecular Design, 15 (3): 247–258, Bibcode:2001JCAMD..15..247T, doi:10.1023/A:1008140021426, PMID 11289078, S2CID 80361
  22. ^ Cooper, Julia C.; Gutbrod, Oliver; Witzemann, Veit; Methfessel, Christoph (1996), "Pharmacology of the nicotinic acetylcholine receptor from fetal rat muscle expressed in Xenopus oocytes", European Journal of Pharmacology, 309 (3): 287–298, doi:10.1016/0014-2999(96)00294-4, PMID 8874153
  23. ^ Carter, Chris R.J.; Cao, Liren; Kawai, Hideki; Smith, Peter A.; Dryden, William F.; Raftery, Michael A.; Dunn, Susan M.J. (2007), "Chain length dependence of the interactions of bisquaternary ligands with the Torpedo nicotinic acetylcholine receptor", Biochemical Pharmacology, 73 (3): 417–426, doi:10.1016/j.bcp.2006.10.011, PMID 17118342
  24. ^ Charton, Yves; Guillonneau, Claude.; Lockhart, Brian; Lestageb, Pierre; Goldsteina, Solo (2008), "Preparation and affinity profile of novel nicotinic ligands", Bioorganic & Medicinal Chemistry Letters, 18 (6): 2188–2193, doi:10.1016/j.bmcl.2007.12.075, PMID 18262785
  25. ^ Walker, Daniel P.; Wishka, Donn G.; Piotrowski, David W.; Jia, Shaojuan; Reitz, Steven C.; Yates, Karen M.; Myers, Jason K.; Vetman, Tatiana N.; Margolis, Brandon J.; Jacobsen, E. Jon; Acker, Brad A.; Groppi, Vincent E.; Wolfe, Mark L.; Thornburgh, Bruce A.; Tinholt, Paula M.; Cortes-Burgos, Luz A.; Walters, Rodney R.; Hester, Matthew R.; Seest, Eric P.; Dolak, Lester A.; Han, Fusen; Olson, Barbara A.; Fitzgerald, Laura; Staton, Brian A.; Raub, Thomas J.; Hajos, Mihaly; Hoffmann, William E.; Li, Kai S.; Higdon, Nicole R.; et al. (2006), "Design, synthesis, structure–activity relationship, and in vivo activity of azabicyclic aryl amides as a7 nicotinic acetylcholine receptor agonists", Bioorganic & Medicinal Chemistry, 14 (24): 8219–8248, doi:10.1016/j.bmc.2006.09.019, PMID 17011782
  26. ^ http://www.envivopharma.com - Nicotinic Alpha7 Acetylcholine Receptor Agonist Program Archived 2010-01-07 at the Wayback Machine
  27. ^ a b Rollema, H.; Chambers, L.K; Coe, J.W.; Glowa, J.; Hurst, R.S.; Lebel, L.A; Lu, Y.; Mansbach, R.S.; Mather, R.J.; Rovetti, C.C.; Sands, S.B.; Schaeffer, E.; Schulz, D.W.; Tangley III, F.D.; Williams, K.E. (2007), "Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid", Neuropharmacology, 52 (3): 985–994, doi:10.1016/j.neuropharm.2006.10.016, PMID 17157884, S2CID 53267460
  28. ^ a b "CHAMPIX 0.5 mg film-coated tablets; CHAMPIX 1 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (eMC)". emc.medicines.org.uk. Archived from the original on 2012-12-24.
  29. ^ Greenblatt, H.M.; Kryger, G.; Lewis, T.; Silman, I.; Sussman, J.L (1999), "Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 angstrom resolution", FEBS Letters, 463 (3): 321–326, doi:10.1016/S0014-5793(99)01637-3, PMID 10606746
  30. ^ "Reminyl XL 8mg, 16mg and 24mg prolonged release capsules - Summary of Product Characteristics (SmPC) - (eMC)". emc.medicines.org.uk. Archived from the original on 2012-12-24.
  31. ^ Dani, John A.; Biasi, Mariella De (2001), "Cellular mechanisms of nicotine addiction", Pharmacology Biochemistry and Behavior, 70 (4): 439–446, doi:10.1016/S0091-3057(01)00652-9, PMID 11796143, S2CID 12960054
  32. ^ a b c d Rang, H. P. (2003), Pharmacology, Edinburgh: Churchill Livingstone, ISBN 978-0-443-07145-4 Page 149
  33. ^ XI, Zheng-xiong; Spiller, Krista; Gardner, Eliot L. (2009), "Mechanism-based medication development for the treatment of nicotine dependence", Acta Pharmacol Sin, 30 (6): 723–739, doi:10.1038/aps.2009.46, PMC 3713229, PMID 19434058, ProQuest 213027402
  34. ^ http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/16968s022lbl.pdf [bare URL PDF]
  35. ^ Tuba, Zoltan; Maho, Sandor; Vizi, E. Sylvester (2002), "Synthesis and Structure-Activity Relationships of Neuromuscular Blocking Agents", Current Medicinal Chemistry, 9 (16): 1507–1536, doi:10.2174/0929867023369466, PMID 12171561, ProQuest 215095660
  36. ^ "Anectine Injection - Summary of Product Characteristics (SmPC) - (eMC)". emc.medicines.org.uk. Archived from the original on 2012-12-24.
  37. ^ Carroll, F. Ivy (2004), "Epibatidine structure-activity relationships", Bioorganic & Medicinal Chemistry Letters, 14 (8): 1889–1896, doi:10.1016/j.bmcl.2004.02.007, PMID 15050621
  38. ^ Unless else specified in boxes, then reference is: Table 10-3 in: Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007), Rang & Dale's pharmacology, Edinburgh: Churchill Livingstone, ISBN 978-0-443-06911-6
  39. ^ Matera, Carlo; Papotto, Claudio; Dallanoce, Clelia; De Amici, Marco (August 2023). "Advances in small molecule selective ligands for heteromeric nicotinic acetylcholine receptors". Pharmacological Research. 194: 106813. doi:10.1016/j.phrs.2023.106813. hdl:2434/978688.
  40. ^ "Roche - Pharmaceuticals Pipeline". Archived from the original on 2009-12-25. Retrieved 2009-12-21.
  41. ^ "Memory Pharmaceuticals Achieves Enrollment Goal For Phase 2 Study Of MEM 3454 In Cognitive Impairment Associated With Schizophrenia".
  42. ^ "Drug Development". Archived from the original on 2006-10-03. Retrieved 2009-12-21.
  43. ^ "Programs - EnVivo". Archived from the original on 2009-08-06. Retrieved 2009-12-21.
edit

  Media related to Nicotinic agonists at Wikimedia Commons

Retrieved from "https://en.wiki.x.io/w/index.php?title=Nicotinic_agonist&oldid=1244167043"